ライフサイエンスコーパス: vaccine strain

1 pulmonary infection with F. tularensis live vaccine strain.

2 ortugal/79906/2009 (H10N7) as a suitable H10 vaccine strain.

3 pulmonary infection with F. tularensis live vaccine strain.

4 CHMI using Pf parasites heterologous to the vaccine strain.

5 nverse was observed for the parallel African vaccine strain.

6 ar antigens, afforded protection to only the vaccine strain.

7 vation of PTEN compared with a virulent live vaccine strain.

8 activity in membranes of F. tularensis live vaccine strain.

9 structed using the live-attenuated HSV-1 VC2 vaccine strain.

10 ating strain is never fewer than that in the vaccine strain.

11 ies barrier and warrants selection of an H10 vaccine strain.

12 ne, mg0359, unique to M. gallisepticum ts-11 vaccine strain.

13 protein in the background of the current MV vaccine strain.

14 tion inhibition antibody titers against each vaccine strain.

15 cally distinct from the current A(H1N1)pdm09 vaccine strain.

16 significantly lower levels than against the vaccine strain.

17 eason's B/Massachusetts/02/2012-like clade 2 vaccine strain.

18 ower in mice immunized with the conventional vaccine strain.

19 against the 2009 pandemic influenza A(H1N1) vaccine strain.

20 polymerases might serve as live, attenuated vaccine strains.

21 rt limited T cell immunity restricted to the vaccine strains.

22 rrant further development as live-attenuated vaccine strains.

23 [DISC]) strain to generate a series of DISC vaccine strains.

24 tment between the G1P[5] and G6P[8] parental vaccine strains.

25 cluster that were genetically distinct from vaccine strains.

26 ere immunized at birth with one of three BCG vaccine strains.

27 proinflammatory reaction to live attenuated vaccine strains.

28 tion neutralization test (PRNT) against both vaccine strains.

29 ed strains, including 2 vdG1P[8] reassortant vaccine strains.

30 aseptic meningitis in recipients of certain vaccine strains.

31 d nonreactogenic live-attenuated V. cholerae vaccine strains.

32 berculosis drugs and attenuated tuberculosis vaccine strains.

33 dentity between the two variants and classic vaccine strains.

34 age matches with recommended influenza virus vaccine strains.

35 e strain, and 15 mug of haemagglutinin per B vaccine strain) (1) by microneedle patch or (2) by intra

36 cted in 82% of specimens (84% wild-type, 15% vaccine-strain, 1% possible vaccine-wild-type recombinan

37 (fluvirin: 18 mug of haemagglutinin per H1N1 vaccine strain, 17 mug of haemagglutinin per H3N2 vaccin

38 as a model the yellow fever virus (YFV) live vaccine strain 17D-204 and its wild-type parental strain

39 for efficient CHIKV replication using CHIKV vaccine strain 181/25 and clinical isolate SL15649.

40 zation, which likely mediates attenuation of vaccine strain 181/25.

41 H3 isolates from those against egg-grown H3 vaccine strain A/Texas/50/2012 (TX/12e).

42 he notable exception of the responses to the vaccine strain A244 Env that were dominated by V2, where

43 f attenuation of the Sabin 2 oral poliovirus vaccine strain (A481 in the 5'-untranslated region [5'-U

44 the clinical-like strain TB40-BAC4 or to the vaccine strain AD169varATCC, prior to their long-term ma

45 able to detect RNA from five currently used vaccine strains, AIK-C, CAM-70, Edmonston-Zagreb, Morate

46 o achieved in cattle with a mixture of three vaccine strains, albeit at a lesser level than in sheep.

47 sd mutant may be a promising live attenuated vaccine strain and a biosafe strain for consideration of

48 ce glycosaminoglycans are utilized by both a vaccine strain and a clinical isolate of CHIKV to mediat

49 s of both classes were identified within the vaccine strain and among sensu stricto strains.

50 ers within 1 week of delivery, regardless of vaccine strain and HIV exposure status.

51 luded B. mallei DeltatonB Deltahcp1 (CLH001) vaccine strain and investigated its ability to protect a

52 Living F. tularensis live vaccine strain and Schu S4 did not stimulate secretion o

53 of GFP-expressing F. tularensis strains live vaccine strain and Schu S4 was quantified with high effi

54 and the encoding locus structure between the vaccine strain and the sensu stricto strains than among

55 estigated the ability of the attenuated live vaccine strain and virulent Schu S4 strain of F. tularen

56 irculate in the United States and from swine vaccine strains and also showed antigenic drift from hum

57 emonstrated the genetic stabilities of these vaccine strains and also the complementing cell line.

58 drift, which can lead to mismatches between vaccine strains and circulating strains.

59 ive, they are affected by mismatches between vaccine strains and circulating strains.

60 erful framework for rational design of safer vaccine strains and for forecasting virulence of viruses

61 erivatives have been used for development of vaccine strains and vaccine adjuvants.

62 onitoring is necessary to assess the role of vaccine strains and vaccine-reassortant strains in pedia

63 The six MAbs neutralized vaccine strains and virulent strains of poliovirus.

64 ally important antigenic differences between vaccine strains and wild-type rabies viruses.

65 h amino acid identity between the E genes of vaccine strains and wild-type viruses from trial partici

66 s in vaccinated children (both wild-type and vaccine-strain) and 230 per 100,000 person-years in unva

67 ne strain, 17 mug of haemagglutinin per H3N2 vaccine strain, and 15 mug of haemagglutinin per B vacci

68 Using HRVs, including the Rotarix RV1 vaccine strain, and ARVs, we evaluated host susceptibili

69 red with the A/Texas/50/2012-like clade 3C.1 vaccine strain, and more than half were antigenically mi

70 st strains were antigenically similar to the vaccine strain, and no resistance or known pathogenicity

71 ubstitutions were found to be unique to this vaccine strain, and their role in virulence attenuation

72 genome differences among vaccine revertants, vaccine strains, and field isolates, whole-genome sequen

73 y, some vaccines may revert to virulence and vaccine strains are generally difficult to distinguish f

74 More than 20 genetically distinct BCG vaccine strains are in use worldwide.

75 enough diversity to suggest updates in swine vaccine strains are needed.

76 d between the clusters to suggest updates in vaccine strains are needed.

77 sid protein VP1 region had diverged from the vaccine strain at 12.3% of nucleotide positions, and the

78 accine efficacy against viruses matching the vaccine strain at V2 residue 169.

79 urvival of Salmonella enterica serovar Typhi vaccine strains at pHs 3.0 and 2.5 to compensate for the

80 ynthesis, was introduced into two Salmonella vaccine strains attenuated by auxotrophic traits or by t

81 is genetically distinct from the commercial vaccine strains B1 and LaSota, which belong to genotype

82 ination with the Mycobacterium bovis-derived vaccine strain bacille Calmette-Guerin (BCG).

83 In sharp contrast, the vaccine strain bacille Calmette-Guerin as well as RD-1 a

84 ss in animal models, including an attenuated vaccine strain based on an isolate from La Reunion incor

85 f the existing vaccine candidate or an HSV-2 vaccine strain based on viruses from that region.

86 ncovers the evolutionary strategies by which vaccine strains become pathogenic and provides a powerfu

87 ive antibodies against not only the dominant vaccine strains but also minor circulating strains that

88 ainst plague, we developed a live-attenuated vaccine strain by deleting the Braun lipoprotein (lpp) a

89 anslational viability of the HSV-1 0DeltaNLS vaccine strain by demonstrating that, while it is compar

90 One specimen was recognized as vaccine strain by identifying vaccine-associated SNPs.

91 ome differs from the 1950s-era prototype and vaccine strains by a lateral gene transfer, substituting

92 Here we used the Junin virus vaccine strain Candid 1 to determine whether mouse cells

93 ave been documented, and a highly attenuated vaccine strain (Candid #1) was generated and used to vac

94 e applied to identify antigenic variants and vaccine strain candidates for pathogens with rapid antig

95 ur results indicate that the live Salmonella vaccine strain chi9447 harboring pYA4535 efficiently sti

96 ly interested in the F. tularensis LVS (live vaccine strain) clpB (FTL_0094) mutant because this stra

97 to protect against seasonal infections, and vaccine strain compositions are updated every year.

98 of O-antigen-specific antibodies elicited by vaccine strains containing a homologous O antigen.

99 urthermore, to test if mixtures of different vaccine strains could be tolerated, we tested cocktails

100 e, nonreplicating avirulent uracil auxotroph vaccine strain (cps) of Toxoplasma triggers novel innate

101 ttenuated Vibrio cholerae O1 classical Inaba vaccine strain CVD 103-HgR, elicits seroconversion of vi

102 Prototype attenuated vaccine strains CVD 1921 and CVD 1941, derived from the

103 HAI titers of 1:40 or more to the influenza vaccine strains decreased from more than 56% in the firs

104 In the context of an attenuated vaccine strain delivering the pneumococcal antigen PspA,

105 The growth curves of three recent vaccine strains demonstrated that the qRT-PCR signal det

106 least 1 (ID 69% vs IM 68%; P = .7) of the 3 vaccine strains did not differ significantly between ID

107 Africa, we examined the ability of an HSV-2 vaccine strain, dl5-29, and other HSV-2 replication-defe

108 e genetics system for the live-attenuated MV vaccine strain Edmonston-Zagreb (EZ), allowing recovery

109 e tested the ability of oral M. tuberculosis vaccine strains expressing SIV Env and Gag proteins, fol

110 irus (NDV) recombinants, based on the LaSota vaccine strain, expressing glycoproteins B (gB) and D (g

111 ysis of the M. gallisepticum live attenuated vaccine strain F and the virulent strain R(low), reporte

112 could be engineered into a thermolabile NDV vaccine strain for developing novel thermostable NDV vac

113 otential candidate live attenuated influenza vaccine strains for human use.

114 variants of influenza viruses and to select vaccine strains for use in controlling and preventing di

115 le to distinguish the M. gallisepticum ts-11 vaccine strain from field isolates.

116 ches to quickly distinguish M. gallisepticum vaccine strains from field isolates.

117 oculation of the Francisella tularensis live vaccine strain (Ft-LVS).

118 o in response to Francisella tularensis Live Vaccine Strain (Ft. LVS) infection.

119 rase) deletion mutant of Ft. live attenuated vaccine strain (Ft.LVS), designated Ft.LVS::Deltawzy, wa

120 Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly h

121 In contrast, the MLV vaccine strain has a significantly reduced ability to in

122 The RdRp of the Sabin I vaccine strain has Thr-362 changed to Ile.

123 ntrast, A. marginale subsp. centrale (Israel vaccine strain) has an identical life cycle but replicat

124 A number of live attenuated RSV vaccine strains have been developed in which the small h

125 The mutated vaccine strain hemagglutinin binds in addition the ubiqu

126 Vaccine-strain herpes zoster (HZ) can occur after varice

127 The reduction in vaccine strain heterogeneity following tick passage did

128 could bind infectious virions (including the vaccine strains HIV-1 CM244 and HIV-1 MN and an HIV-1 st

129 lipid (FtL) from Francisella tularensis live-vaccine strain (i) induces FtL-specific B-1a to produce

130 he necessary characteristics for a potential vaccine strain: (i) viral protein expression in noncompl

131 id not alter the attenuated phenotype of the vaccine strain in a lethal mouse model.

132 ging G9 porcine RV strains and a human G1 RV vaccine strain in a susceptible host (swine) will allow

133 ompared with those of the WT strains and the vaccine strain in two different murine models: infant CD

134 Shedding of RotaTeq vaccine strains in 7 of 13 infants was associated with u

135 ations in the guaBA operon in S. flexneri 2a vaccine strains in clinical studies, we developed a seri

136 the immune response induced by different BCG vaccine strains in newborn infants.

137 easily adoptable method to identify measles vaccine strains in suspect cases.

138 ng strains that can evolve into the dominant vaccine strains in the future.

139 eplicating, live attenuated uracil auxotroph vaccine strains in the type II Deltaku80 genetic backgro

140 responses revealed that SchuS4, but not live vaccine strain, induced IFN-beta following infection of

141 lipid (FtL) from Francisella tularensis live vaccine strain induces splenic FtL-specific B-1a to moun

142 Current data on which BCG vaccine strain induces the optimal immune response in hu

143 In contrast to the attenuated live vaccine strain, infection of human dendritic cells with

144 Previous studies suggest that BCG vaccine strain influences the immune response and protec

145 ensis strain SchuS4, but not attenuated live vaccine strain, inhibit inflammatory responses in vitro

146 ation "bottleneck." We demonstrated that the vaccine strain is genetically heterogeneous at 46 chromo

147 ule inhibition or by genetic modification of vaccine strains, is expected to reduce the pathogenic po

148 pulmonary infection with F. tularensis live vaccine strain, its production is tightly regulated by I

149 ure of the parental strain, whereas the live vaccine strain lacks diversity according to multiple ind

150 86.5 to 87.9% identities, respectively, with vaccine strain LaSota, indicative of considerable divers

151 a virulence factor of the F. tularensis live vaccine strain (LVS) and demonstrated that a DeltatolC m

152 racellular trafficking of F. tularensis Live Vaccine Strain (LVS) and LVS with disruptions of wbtDEF

153 from mice vaccinated with F. tularensis Live Vaccine Strain (LVS) and related attenuated strains, we

154 spiratory infection with the attenuated Live Vaccine Strain (LVS) and the highly virulent SchuS4 stra

155 of the F. tularensis subsp. holarctica live vaccine strain (LVS) in macrophages and epithelial cells

156 during pulmonary Francisella tularensis live vaccine strain (LVS) infection.

157 ntly available unlicensed F. tularensis live vaccine strain (LVS) is needed to protect against intent

158 ined the transcriptional profile of the live vaccine strain (LVS) of F. tularensis grown in the FL83B

159 ificantly resistant to infection by the live vaccine strain (LVS) of F. tularensis Resistance is char

160 intradermal challenge of mice with the live vaccine strain (LVS) of F. tularensis, splenic IL-10 lev

161 f A549 airway epithelial cells with the live vaccine strain (LVS) of F. tularensis.

162 on against secondary challenge with the live vaccine strain (LVS) of Francisella tularensis.

163 del of pulmonary infection by using the live vaccine strain (LVS) of Francisella tularensis.

164 (IL-17) confers protection against the live vaccine strain (LVS) of Francisella.

165 First, inactivation of FTL_0325 from live vaccine strain (LVS) or FTT0831c from Schu S4 resulted i

166 When LPS from the attenuated live vaccine strain (LVS) or the highly virulent Schu S4 stra

167 macrophages infected with F. tularensis live vaccine strain (LVS) or the virulent SchuS4 strain are d

168 the lethality of primary F. tularensis live vaccine strain (LVS) pulmonary infection in mice that ar

169 rmal inoculation with the F. tularensis live vaccine strain (LVS) results in a robust Th1 response in

170 We employed Francisella tularensis live vaccine strain (LVS) to study mechanisms of protective i

171 4) as being important for F. tularensis live vaccine strain (LVS) virulence.

172 though an attenuated strain, dubbed the live vaccine strain (LVS), is given to at-risk laboratory per

173 esis of F. tularensis subsp. holarctica live vaccine strain (LVS), we identified FTL_0883 as a gene i

174 hal doses of the Francisella tularensis live vaccine strain (LVS).

175 through vaccination with the attenuated live vaccine strain (LVS).

176 ion during infection with F. tularensis live vaccine strain (LVS).

177 derophore utilization by the attenuated live vaccine strain (LVS).

178 d deletion mutants of the F. tularensis live vaccine strain (LVS).

179 and DeltafopC mutants against pulmonary live-vaccine-strain (LVS) challenge and found that both strai

180 Overall, the data suggest that the HSV-1 VC2 vaccine strain may be used as a viral vector for the vac

181 bition of PA-X expression in influenza virus vaccine strains may provide a novel way of safely attenu

182 siblings; the proband developed disseminated vaccine strain measles following routine immunization, w

183 arental (wild-type [WT]) recombinant Moraten vaccine strain measles virus (MV) or isogenic knockout m

184 The efficacy of LAIV against vaccine-strain moderate-to-severe LCI was 56.7% (95% con

185 Importantly, both the attenuated vaccine strain MP12 and the fully virulent strain ZH548

186 However, due to antigenic drift, vaccine strains must be periodically updated.

187 However, as a result of antigenic drift, vaccine strains must be regularly updated to reflect cur

188 However, vaccine strains must be updated to reflect current strai

189 time, a process called antigenic drift, and vaccine strains must be updated to remain effective.

190 cobacterium tuberculosis with the attenuated vaccine strain Mycobacterium bovis bacillus Calmette-Gue

191 -type PPRV or either of two established PPRV vaccine strains, Nigeria/75/1 or Sungri/96.

192 e observed that a newly generated Salmonella vaccine strain not only conferred superior protection co

193 viruses (Yamagata and Victoria lineages) and vaccine strains occurs frequently.

194 de identity in all 10 genome segments with a vaccine strain of BTV-10 from the United States.

195 egments of RSArrrr/16 group closely with the vaccine strain of BTV-16 (RSAvvvv/16) that was derived f

196 cine.IMPORTANCE The live-attenuated Candid#1 vaccine strain of Junin virus is used to protect against

197 ld-type mice cleared Candid 1 (JUNV C1), the vaccine strain of Junin virus, more rapidly than did TLR

198 Candid#1 (Cd1) is an attenuated vaccine strain of Junin virus, the causative agent of Ar

199 glycoprotein of the Candid#1 live-attenuated vaccine strain of JUNV in MACV replication and its abili

200 ip between bat mumps virus (BMV) and the JL5 vaccine strain of mumps virus (MuVJL5), we rescued a chi

201 While sera from animals vaccinated with the vaccine strain of RPV showed cross-neutralizing ability

202 e markers in a single recombinant attenuated vaccine strain of Salmonella enterica serotype Typhimuri

203 virus infection against not only historical vaccine strains of H3N2 but also a set of cocirculating

204 Edmonston vaccine strains of measles virus (MV) have shown signifi

205 Edmonston vaccine strains of measles virus (MV) have significant a

206 induction was similar between wild-type and vaccine strains of MeV.

207 , Moraten, Rubeovax, Schwarz, and Zagreb are vaccine strains of the Edmonston lineage, whereas CAM-70

208 rotected from rinderpest by inoculation with vaccine strains of the related morbillivirus, peste des

209 Although VZV vaccine strain Oka is attenuated, it can cause mild vari

210 ABV expressing the attachment protein of CDV vaccine strain Onderstepoort succumbed to infection with

211 Salmonella may be useful as live attenuated vaccine strains or as vehicles for heterologous antigen

212 a virus subtypes to improve the stability of vaccine strains or components.

213 Wild type (live vaccine strain) or catalase-deficient F. tularensis (Del

214 ow evidence of antigenic drift away from the vaccine strain over time.

215 e attenuated infectious bursal disease virus vaccine strain PBG98.

216 Using a dengue virus serotype 2 (DENV-2) vaccine strain (PDK53), we show that infection creates a

217 r alternative etiology and with isolation of vaccine-strain poliovirus.

218 ns exposed to the egg-adapted 2016-2017 H3N2 vaccine strain poorly neutralize a glycosylated clade 3C

219 king studies demonstrated uptake of the Bp82 vaccine strain predominately by neutrophils in vaccine-d

220 e top candidates dramatically improved viral vaccine strain production.

221 glycoprotein-deletion variant of the SAD-B19 vaccine strain rabies virus (RABV) has been the reagent

222 lent vaccine candidates based on recombinant vaccine strain rabies virus particles, which concurrentl

223 ive PCR [RT-qPCR]) that can identify measles vaccine strains rapidly, with high throughput, and witho

224 ating new pandemic 2009 virus; Arg226 in the vaccine-strain RBS accounts for the restriction.

225 ng mice inoculated with an attenuated rabies vaccine strain, recombinant LBNSE.

226 Infection of cells with the RVFV MP-12 vaccine strain reduced p62 protein levels to below the d

227 ommon ancestor, probably an ancient smallpox vaccine strain related to horsepox virus.

228 luenza vaccines mainly depends upon how well vaccine strains represent circulating viruses; mismatche

229 lier viruses and WHO-recommended prepandemic vaccine strains representing these clades.

230 y, a genetic screen using the iglE-null live vaccine strain resulted in the identification of key reg

231 NA clone of the highly attenuated Jeryl Lynn vaccine strain (rJL).

232 he vaccine vector strain that can reduce the vaccine strain's ability to interact with host lymphoid

233 e significantly lower than those against the vaccine strain Sabin-1, two genetically distinct WPV1s i

234 porter gene expression, in contrast with the vaccine strain SAD.

235 l approaches that may complement the current vaccine strain selection process, we selected antigenic

236 he antigenic match of hemagglutinin (HA) for vaccine strain selection, and most vaccines rely on HA i

237 To improve vaccine strain selection, human serologic testing on vac

238 difficulties in both clinical diagnosis and vaccine strain selection.

239 on by traditional methods, thus complicating vaccine strain selection.

240 Importantly, these candidate vaccine strains showed strong protective efficacy agains

241 nuation purposes, generating the recombinant vaccine strains SLT17 (pCZ1) and SLT18 (pCZ1).

242 somewhat mitigated in combination with other vaccine strain-specific mutations, which might be compen

243 hydrolase in F. tularensis Schu S4 and live vaccine strain strains, in H. pylori 26695 strain and in

244 Live attenuated vaccine strains, such as type I nonreplicating uracil au

245 Candidate Salmonella vaccine strains synthesizing pneumococcal surface protei

246 we determined the structure of an attenuated vaccine strain, TC-83, of VEEV to 4.4 A resolution.

247 of two clones of VACV-IOC, a unique smallpox vaccine strain that contributed to smallpox eradication

248 broad implications for rational selection of vaccine strains that do not contain prolines in antigeni

249 st the live attenuated West Nile virus (WNV) vaccine strain, the nonstructural (NS) 4B-P38G mutant.

250 ons, and for many live attenuated Salmonella vaccine strains, the acid tolerance response is unable t

251 Compared to common vaccine strains, the African strain contains a previousl

252 . tularensis subsp. holarctica (type B) live vaccine strains, thereby demonstrating the vaccine poten

253 uberculosis from the Bacille-Calmette-Guerin vaccine strain, they currently lack the specificity to d

254 tions were moved to an attenuated Salmonella vaccine strain to evaluate their effects on immunogenici

255 The first comparison of a live RNA viral vaccine strain to its wild-type parental strain by deep

256 essed for the development of live-attenuated vaccine strains to combat HFAs.

257 le-genome sequencing of the M. gallisepticum vaccine strain ts-11 and several "ts-11-like" strains is

258 We also determined that vaccine strains ts-11 and 6/85 produce little to no H2O2

259 few genetic loci commonly affected in F and vaccine strains ts-11 and 6/85, which would correlate wi

260 falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination.

261 Currently licensed vaccine strains used in animals are unacceptable for hum

262 -2D (LdWT) and characterized the LdCen (-/-) vaccine strain using bioinformatics tools.

263 that can be used for screening and selecting vaccine strains using immunoinformatics tools and a huma

264 05) to Brucella vaccine protection efficacy: vaccine strain, vaccination host (mouse) strain, vaccina

265 number and proportion of HZ cases caused by vaccine-strain varicella zoster virus (VZV), assessed th

266 , the majority (78%) captured the infectious vaccine strain virus (CM244), while a smaller proportion

267 lizing antibodies against tier 1 and tier 2 (vaccine strain) viruses.

268 The live, attenuated varicella vaccine strain (vOka) is the only licensed therapeutic v

269 rase chain reaction to identify wild-type or vaccine-strain VZV.

270 Immunogenicity against the vaccine strain was assessed 21 days after the first and

271 nization with a live attenuated Burkholderia vaccine strain was dependent primarily on generation of

272 17D-204 was observed, demonstrating that the vaccine strain was derived by discrete mutation of Asibi

273 either cryopreservation or cell culture, the vaccine strain was maintained for decades by sequential

274 Furthermore, another US vaccine strain was more efficacious against US than agai

275 sive drift away from the A/California/7/2009 vaccine strain was observed at both the nucleotide and a

276 istinguishable from that of the 181/clone 25 vaccine strain was obtained by the simultaneous expressi

277 Sequence divergence relative to vaccine strains was substantial, likely contributes to o

278 Candid1, a live-attenuated Junin virus vaccine strain, was developed during the early 1980s to

279 species barrier and to identify a candidate vaccine strain, we evaluated the in vitro and in vivo pr

280 tial disabled infectious single cycle (DISC) vaccine strain, we used a reverse genetics system to res

281 ive immune mechanisms conferred by these two vaccine strains, we examined the efficacy of the F. novi

282 against the 2009 pandemic influenza A(H1N1) vaccine strain were significantly enhanced, compared wit

283 strain of F. tularensis SCHU S4 and the live vaccine strain were used to investigate the contribution

284 dose (LD(5)(0)) analyses showed that the NTS vaccine strains were all highly attenuated in mice.

285 ttended influenza during a season when all 3 vaccine strains were antigenically similar to circulatin

286 The complete genomic sequences of 9 measles vaccine strains were compared with the sequence of the E

287 The vaccine strains were confirmed to be attenuated in vivo

288 ns during this era, but the chosen wild-type vaccine strains were not able to elicit antibodies with

289 These vaccine strains were tested for immunogenicity in Africa

290 strains with O antigens not expressed by the vaccine strains, whereas antibodies to the LPS core and

291 ttenuated herpes simplex virus 1 (HSV-1) VC2 vaccine strain, which has been shown to be unable to ent

292 cidence of HZ cases from reactivation of the vaccine strain, which in the long term will likely outnu

293 HAI titers against the current A(H1N1)pdm09 vaccine strain, which lacks this mutation.

294 mmunity response in contrast to M protein of vaccine strains, which have lost this property.

295 virus is critical for accurate selection of vaccine strains, which is important for effective preven

296 3) season's B/Wisconsin/01/2010-like clade 3 vaccine strain, while only 17% clustered with the curren

297 ce immunized with the auxotrophic Salmonella vaccine strain with the deletion mutation Delta(wza-wcaM

298 In Salmonella vaccine strains with RDAS, the strain with the Delta(wza

299 lly similar to the A/California/07/2009-like vaccine strain, with an adjusted VE of 71% (95% confiden

300 We used the live attenuated vaccine strain YFV-17D, which contains many mutations co